Pasithea Therapeutics Corp (NASDAQ:KTTA) — Market Cap & Net Worth
Market Cap & Net Worth: Pasithea Therapeutics Corp (KTTA)
Pasithea Therapeutics Corp (NASDAQ:KTTA) has a market capitalization of $18.84 Million ($18.84 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #25220 globally and #5112 in its home market, demonstrating a 22.01% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pasithea Therapeutics Corp's stock price $0.84 by its total outstanding shares 22398920 (22.40 Million). Analyse how efficiently does Pasithea Therapeutics Corp generate cash to see how efficiently the company converts income to cash.
Pasithea Therapeutics Corp Market Cap History: 2021 to 2026
Pasithea Therapeutics Corp's market capitalization history from 2021 to 2026. Data shows change from $792.92 Million to $18.84 Million (-61.68% CAGR).
Index Memberships
Pasithea Therapeutics Corp is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #729 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2390 of 3165 |
Weight: Pasithea Therapeutics Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Pasithea Therapeutics Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pasithea Therapeutics Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
340.66x
Pasithea Therapeutics Corp's market cap is 340.66 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $792.92 Million | $15.06K | -$2.17 Million | 52643.86x | N/A |
| 2022 | $287.60 Million | $486.56K | -$13.94 Million | 591.09x | N/A |
| 2023 | $165.75 Million | $486.56K | -$15.96 Million | 340.66x | N/A |
Competitor Companies of KTTA by Market Capitalization
Companies near Pasithea Therapeutics Corp in the global market cap rankings as of May 4, 2026.
Key companies related to Pasithea Therapeutics Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Pasithea Therapeutics Corp Historical Marketcap From 2021 to 2026
Between 2021 and today, Pasithea Therapeutics Corp's market cap moved from $792.92 Million to $ 18.84 Million, with a yearly change of -61.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $18.84 Million | -34.81% |
| 2025 | $28.89 Million | -59.05% |
| 2024 | $70.56 Million | -57.43% |
| 2023 | $165.75 Million | -42.37% |
| 2022 | $287.60 Million | -63.73% |
| 2021 | $792.92 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Pasithea Therapeutics Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $18.84 Million USD |
| MoneyControl | $18.84 Million USD |
| MarketWatch | $18.84 Million USD |
| marketcap.company | $18.84 Million USD |
| Reuters | $18.84 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pasithea Therapeutics Corp
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1);… Read more